WO1996034941A1 - Utilisation de la protease de cysteine extracellulaire pour inhiber la proliferation des cellules - Google Patents
Utilisation de la protease de cysteine extracellulaire pour inhiber la proliferation des cellules Download PDFInfo
- Publication number
- WO1996034941A1 WO1996034941A1 PCT/US1996/005997 US9605997W WO9634941A1 WO 1996034941 A1 WO1996034941 A1 WO 1996034941A1 US 9605997 W US9605997 W US 9605997W WO 9634941 A1 WO9634941 A1 WO 9634941A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cysteine protease
- protease
- cells
- proliferation
- neoplastic cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
Definitions
- Metastasis is a process by which tumor cells spread from a tumor to other parts of the body.
- An antimetastasis therapy is a therapy that reduces or eliminates metastases, or can limit metastases.
- methods for evaluating the sensitivity of target cells to Streptococcus extracellular cysteine protease include detection of binding of a Streptococcus cysteine protease to the extracellular matrix and/or detection of proteolytic products generated following hydrolysis of protein components of the extracellular matrix (ECM).
- the cysteine protease retains both the catalytic and binding activities of the native cysteine protease.
- derived from it is meant that the cysteine protease has the amino acid sequence of all or part of a cysteine protease obtained from S. pyogenes.
- a microorganism is considered to be the same as or equivalent to Streptococcus pyogenes if in its genome is a coding sequence for an extracellular cysteine protease which is involved in the pathogenesis of the microorganism.
- the sequence can be naturally occurring, or partially or wholly synthetic.
- the sequence can be truncated as compared to the native protease, or can include additional sequences at the amino and/or carboxy terminals of the protease.
- polypeptides employed in the subject invention need not be identical to a cysteine protease obtainable from S. pyogenes, so long as the subject compounds are able to provide for enzymatic interaction with a substrate of a cysteine protease obtainable from at least one of the strains of S. pyogenes.
- the nucleotide sequence to which the polypeptides "correspond” may exhibit strain-to-strain variation and species-to-species variation.
- the polypeptides can exhibit various changes such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use.
- an ELISA is used to examine the enzymatic activity of each peptide using as substrate component proteins of the ECM.
- the peptides then are further screened for antiproliferative activity against target hyperproliferative cells, both in vitro and in vivo.
- the antimetastasis therapy increases survival times by at least about 30% over the survival times typical for the particular type of cancer in the absence of an antimetastasis therapy. More preferably, survival times are increased by at least about 50%, and most preferably by at least about 70%.
- one or more transforming growth factors may be employed, as well as one or more interferons or tumor necrosis factor may be employed.
- active fragments can be employed, as well as chimeras in which a portion of one related molecule is joined to a portion of another related molecule.
- the composition will vary widely depending upon its intended purpose, the desired ratio of the components, as well as the nature of the components and their activity. Thus, depending upon the nature of the malignancy, its response to the different components and their synergistic activity, the ratios of the various components will vary. For the most part, the amount of cysteine protease will generally be in the range of about 0.5 to 25 % of the amount of Oncostatin M or congener employed by itself.
- the zymogen form can be purified with a closely similar protocol, except cysteine is omitted from the medium and the culture is incubated in the absence of supplemental CO 2 .
- thermocycling parameters were: denaturation at 94°C for 1 minute, annealing at 55°C for 2 minutes, and extension at 72°C for 2.5 minutes for a total of 30 cycles. A final extension at 72°C for 15 minutes was used.
- a linker with two copies of the recognition sequence for the enzyme SapI (GCTCTTC) is used to create six base deletions (three bases on each end of the linker), or random two amino acid deletions, across the speB gene. Flanking bases are also randomized by filling the ends of the target sequence after linker excision, then inserting a second blunt end linker that includes a random sequence in place of the Ns. The second linker is then removed by digestion with Sapl and the target sequence is ligated to generate substitutions.
- the proteolytically inactive precursor of the streptococcal protease is thought to be a member of the family of superantigenic streptococcal and staphylococcal exotoxins (Marrack and Kappler, Science, 248:705-11 (1990); Tomai et al, Infec. Immun., 60:701-05 (1992), Abe et al., J. Immunol., 146:3747-50 (1991). Since superantigens stimulate T-cells to release tumor necrosis factor (Miethke et al., J. Exp. Med., 175:91-98
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des compositions comprenant une protéase de cystéine provenant par exemple d'espèces streptococciques. Ces compositions trouvent une application dans la modulation de la croisance des cellules, notamment en tant qu'agent inhibiteur de la prolifération cellulaire, et plus particulièrement des cellules tumorales. Les compositions inhibant la croissance cellulaire peuvent également comprendre un adjuvant. Des méthodes de criblage pour identifier les cellules tumorales sensibles aux effets de modulation de la croissance de la cystéine-protéase sont également décrites.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU57188/96A AU5718896A (en) | 1995-05-01 | 1996-04-30 | Use of extracellular cysteine protease to inhibit cell proli feration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43269295A | 1995-05-01 | 1995-05-01 | |
US08/432,692 | 1995-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996034941A1 true WO1996034941A1 (fr) | 1996-11-07 |
Family
ID=23717219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/005997 WO1996034941A1 (fr) | 1995-05-01 | 1996-04-30 | Utilisation de la protease de cysteine extracellulaire pour inhiber la proliferation des cellules |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5718896A (fr) |
WO (1) | WO1996034941A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162405A1 (en) * | 2006-12-14 | 2009-06-25 | Yong Qian | Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells |
US7750132B2 (en) * | 1997-06-25 | 2010-07-06 | The United States Of America As Represented By The Secretary Of The Navy | Altered superantigen toxins |
US20150132285A1 (en) * | 2005-10-03 | 2015-05-14 | Yong Qian | Proteinase-engineered Cancer Vaccine Induces Immune Responses to Prevent Cancer and to Systemically Kill Cancer Cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4844897A (en) * | 1985-09-13 | 1989-07-04 | Hiroshi Maeda | Anti-tumor protease preparations |
-
1996
- 1996-04-30 AU AU57188/96A patent/AU5718896A/en not_active Abandoned
- 1996-04-30 WO PCT/US1996/005997 patent/WO1996034941A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4844897A (en) * | 1985-09-13 | 1989-07-04 | Hiroshi Maeda | Anti-tumor protease preparations |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7750132B2 (en) * | 1997-06-25 | 2010-07-06 | The United States Of America As Represented By The Secretary Of The Navy | Altered superantigen toxins |
US20150132285A1 (en) * | 2005-10-03 | 2015-05-14 | Yong Qian | Proteinase-engineered Cancer Vaccine Induces Immune Responses to Prevent Cancer and to Systemically Kill Cancer Cells |
US9669082B2 (en) * | 2005-10-03 | 2017-06-06 | Yong Qian | Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells |
US20090162405A1 (en) * | 2006-12-14 | 2009-06-25 | Yong Qian | Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells |
Also Published As
Publication number | Publication date |
---|---|
AU5718896A (en) | 1996-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hu et al. | Expression of catalytically active recombinant Helicobacter pylori urease at wild-type levels in Escherichia coli | |
JP3722834B2 (ja) | 細菌輸出タンパク質及びそれらをベースとする無菌体ワクチン | |
Hu et al. | Morganella morganii urease: purification, characterization, and isolation of gene sequences | |
JP3920271B2 (ja) | システイン・プロテアーゼあるいはその断片を含む連鎖球菌を識別するための方法および組成物 | |
WO1996034941A1 (fr) | Utilisation de la protease de cysteine extracellulaire pour inhiber la proliferation des cellules | |
JPH10215885A (ja) | 新規lep | |
JPH1189585A (ja) | 新規Def1 | |
JPH10113189A (ja) | 新規 RNaseP | |
JPH10215882A (ja) | 新規トリプトファニルtRNAシンセターゼ | |
JPH11266880A (ja) | 新規dbpA | |
JPH11235181A (ja) | 新規tig | |
JPH10201484A (ja) | 新規FtsL | |
AU753045B2 (en) | Methods and compositions for identifying streptococcus containing a cysteine protease or fragment thereof | |
US20030049265A1 (en) | Heliobacter pylori antigen | |
JPH11337548A (ja) | 新規DbpB | |
JPH11155582A (ja) | 新規GlmU | |
JPH11235183A (ja) | シグナル認識粒子ポリペプチドおよびポリヌクレオチド | |
JPH11285389A (ja) | 新規ftsY | |
JPH11164695A (ja) | 新規アミノペプチダーゼ | |
JPH11235179A (ja) | pth | |
JPH11253170A (ja) | FtsY | |
JPH11137268A (ja) | GidA1 | |
JP2002504312A (ja) | ribB | |
JPH11332580A (ja) | 新規AmpS | |
JP2002525048A (ja) | Rnasepポリペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |